CZ291376B6 - Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje - Google Patents

Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje Download PDF

Info

Publication number
CZ291376B6
CZ291376B6 CZ19973671A CZ367197A CZ291376B6 CZ 291376 B6 CZ291376 B6 CZ 291376B6 CZ 19973671 A CZ19973671 A CZ 19973671A CZ 367197 A CZ367197 A CZ 367197A CZ 291376 B6 CZ291376 B6 CZ 291376B6
Authority
CZ
Czechia
Prior art keywords
apoa
nucleic acid
variant
seq
sequence
Prior art date
Application number
CZ19973671A
Other languages
Czech (cs)
English (en)
Other versions
CZ367197A3 (cs
Inventor
Gerd Assmann
Patrick Benoit
Eric Bruckert
Patrice Denefle
Nicolas Duverger
Jean-Charles Fruchart
GéRALD LUC
GéRARD TURPIN
Harald Funke
Original Assignee
Rhone-Poulenc Rorer S. A.
Institut Pasteur De Lille
Universite Pierre Et Marie Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S. A., Institut Pasteur De Lille, Universite Pierre Et Marie Curie filed Critical Rhone-Poulenc Rorer S. A.
Publication of CZ367197A3 publication Critical patent/CZ367197A3/cs
Publication of CZ291376B6 publication Critical patent/CZ291376B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
CZ19973671A 1995-05-22 1996-05-20 Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje CZ291376B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine

Publications (2)

Publication Number Publication Date
CZ367197A3 CZ367197A3 (cs) 1998-03-18
CZ291376B6 true CZ291376B6 (cs) 2003-02-12

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ19973671A CZ291376B6 (cs) 1995-05-22 1996-05-20 Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje

Country Status (16)

Country Link
EP (1) EP0827538A1 (sk)
JP (1) JPH11505712A (sk)
KR (1) KR19990021828A (sk)
AU (1) AU717202B2 (sk)
BR (1) BR9608813A (sk)
CA (1) CA2218759A1 (sk)
CZ (1) CZ291376B6 (sk)
FR (1) FR2734568B1 (sk)
HU (1) HUP9802926A3 (sk)
IL (1) IL118336A0 (sk)
MX (1) MX9708727A (sk)
NO (1) NO975367L (sk)
SK (1) SK156397A3 (sk)
TW (1) TW434260B (sk)
WO (1) WO1996037608A1 (sk)
ZA (1) ZA964097B (sk)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP2004500105A (ja) * 2000-03-13 2004-01-08 アムジエン・インコーポレーテツド Ｔ細胞シグナル伝達のアポリポタンパク質−ａ−１調節
JP4344136B2 (ja) 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20040067873A1 (en) 2002-05-17 2004-04-08 Dasseux Jean-Louis H. Method of treating dyslipidemic disorders
US7824709B2 (en) 2003-02-14 2010-11-02 Children's Hospital And Research Center At Oakland Lipophilic drug delivery vehicle and methods of use thereof
WO2005097206A2 (en) 2004-04-06 2005-10-20 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
EP2537526A1 (en) 2006-06-01 2012-12-26 Institut de Cardiologie de Montréal Method and compound for the treatment of valvular stenosis
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8153606B2 (en) * 2008-10-03 2012-04-10 Opko Curna, Llc Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
PT2396017E (pt) 2009-02-16 2015-10-22 Cerenis Therapeutics Holding Sa Miméticos da apolipoproteína a-i
DK2767546T3 (en) 2011-02-07 2019-02-04 Cerenis Therapeutics Holding Sa Lipoprotein complexes and their preparation and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FR2734568B1 (fr) 1997-06-20
CZ367197A3 (cs) 1998-03-18
SK156397A3 (en) 1998-07-08
BR9608813A (pt) 1999-02-17
KR19990021828A (ko) 1999-03-25
NO975367D0 (no) 1997-11-21
CA2218759A1 (fr) 1996-11-28
NO975367L (no) 1997-11-21
EP0827538A1 (fr) 1998-03-11
IL118336A0 (en) 1996-09-12
JPH11505712A (ja) 1999-05-25
AU717202B2 (en) 2000-03-23
WO1996037608A1 (fr) 1996-11-28
FR2734568A1 (fr) 1996-11-29
AU5904896A (en) 1996-12-11
HUP9802926A3 (en) 2001-08-28
ZA964097B (en) 1996-12-06
HUP9802926A2 (hu) 1999-03-29
TW434260B (en) 2001-05-16
MX9708727A (es) 1997-12-31

Similar Documents

Publication Publication Date Title
CZ291376B6 (cs) Varianty apolipoproteinu A-I a farmaceutická kompozice, která je obsahuje
US6258596B1 (en) Variants of apolipoprotein A-I
RU2179034C2 (ru) ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
US6512161B1 (en) Transgenic rabbit that expresses a functional human lipoprotein (a)
KR100330142B1 (ko) 재조합 바이러스 및 유전자 치료에서의 그의 사용
WO1995013374A2 (en) Human and mouse very low density lipoprotein receptors and methods for use of such receptors
PT811074E (pt) Metodos e composicoes de terapia genica para o tratamento de defeitos no metabolismo lipoproteico
CN101506226A (zh) 改良的色素上皮衍生因子变体及其用途
JPH11510389A (ja) 細胞タンパク質の機能を不活性化するためのタンパク質−タンパク質相互作用表面の拡張
CN112639108A (zh) 治疗非综合征性感觉神经性听力损失的方法
CA2239682A1 (en) Nucleic acid sequences of genes of the high mobility group proteins and uses thereof
CA2343099C (en) Role of human kis (hkis) as an inhibitory kinase of the cyclin-dependentkinase inhibitor p27. compositions, methods and uses thereof to control cell proliferation
Germain-Lee et al. NVL: a new member of the AAA family of ATPases localized to the nucleus
US20060142200A1 (en) Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
US20030077757A1 (en) Method of treating aging-related disorders
KR100403893B1 (ko) 글루타메이트 디 카르복실라제(gad) 활성을 암호화하는 재조합바이러스
US5776776A (en) DTEF-1 isoforms and uses thereof
US20020123093A1 (en) Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia
US6894154B2 (en) hKIS compositions and methods of use
JP3606536B2 (ja) ウイルス複製抑制剤
Foresman et al. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: a model for gene therapy of T cell immunodeficiency
US7309606B2 (en) Methods and compositions for treating hypercholesterolemia
WO1994028151A1 (en) Gene therapy for haemophilia
Tomita et al. Therapeutic approach to familial hypercholesterolemia by HVJ-liposomes in LDL receptor knockout mouse
CA2261183A1 (en) Adenoviral transfer vector for the gene transport of a dna sequence

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic
MM4A Patent lapsed due to non-payment of fee

Effective date: 20040520